Navigation Links
pFB-ERV: Retroviral Delivery of the Ecdysone Receptor Proteins

om the 5 LTR; spurious activation/transcription of 3-flanking endogenous genes from the promoter within the 3 LTR will not occur in the SIN vector; and inactivation of the proviral LTRs protects against mobilization of proviral pFB-ERV derivatives by endogenous retroviral structural proteins.

Titer Determination

Vector titer was determined by G418-resistant colony formation. Amphotropic virus was produced by transient transfection using the producer line HW293-A (unpublished data), and viral supernatants were used to infect NIH3T3 cells. In Table 1, the titers for both experiments are on the order of 105 colony forming units (cfu)/ml. Even at high dilutions of supernatant (1:103), which likely give rise to single-copy infected cells in accordance with the Poisson kinetics of viral transduction, colonies are resistant to as high as 1 mg/ml G418 without substantial loss of titer, indicating efficient expression of the Neo gene from the third ORF.

Performance of pFB-ERV in Mass Populations of Infected Cells

Fig.2

NIH3T3 cells were infected with various dilutions of viral supernatant, and one day following infection the cells were transfected with the ecdysone-inducible reporter vector pEGSH-luc. The following day, cells were induced for 20 hours with ponA, then assayed for luciferase activity. In Figure 2 (at an MOI of 1.0), a strong induction is achieved, which is reproducible in separate infected populations.

Analysis of Clonal Isolates of Individual Cells Infected with pFB-ERV

Fig.3

NIH3T3 cells were infected with pFB-ERV supernatants and selected with 600 g/ml G418. Resistant colonies were picked and expanded. In an initial screen, 24 colonies were transfected with reporter vector, and induced
'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. Functional Cloning Using ViraPort Retroviral cDNA Expression Libraries
2. High-Titer Retroviral Vectors for Gene Delivery
3. A New Way to Assess siRNA Delivery Efficiency
4. Efficient Delivery of siRNAs to Human Primary Cells: Electroporation vs. Chemical Transfection
5. Enhanced siRNA Delivery and Long-term Gene Silencing
6. High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells
7. Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice
8. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
9. Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived Tissue
10. Gene-Specific Primers for NMDA Receptor Subunits
11. TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: pFB ERV Retroviral Delivery the Ecdysone Receptor Proteins

(Date:3/5/2015)... March 5, 2015  In response to the incorrect ... Miami, FL on February 12, 2015. Impeto ... strong financial health and their SUDOSCAN® devices have been ... indicated. Furthermore, Impeto prefers to have the courts decide this ... more than 40 articles written by Key Opinion Leaders, ...
(Date:3/4/2015)... In an article published and posted online ... Security review the clinical aspects of diseases caused by ... The article, "Clinical Management of Potential Bioterrorism-Related Conditions," was ... the New England Journal of Medicine . ... and Tom Inglesby—review the clinical management of conditions resulting ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of the "Global Biologics and Biosimilars ... , The Global Biologics and ... in-depth study on the current state of the ... provides a basic overview of the industry including ...
(Date:3/4/2015)... Pa. , March 4, 2015 /PRNewswire/ ... services and technology provider, today announced that ... 10 countries convened at its annual European ... to discuss the use of ... challenges. BioClinica,s eClinical technologies include: the Microsoft ...
Breaking Biology Technology:Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Latest Clinical Information On Bioterrorism Threats 2Global Biologics and Biosimilars Industry Report 2015-2020 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3
... Delcath Systems, Inc. (Nasdaq: DCTH ) today announced ... as a director of the Company, effective December 2, 2008. ... Delcath board is a result of additional commitments to new leadership ... http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) , , Dr. Harold ...
... QUEBEC CITY, Dec. 4 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ... biopharmaceutical company focused on endocrine therapy and oncology, today ... will take part in a panel discussion titled, "Replacing ... upcoming RBC Capital Markets 2008 Healthcare Conference on Wednesday, ...
... (NASDAQ:LIFE), a provider of innovative life science research ... for next-generation genomic analysis, the SOLiD™ System, has ... Year for 2008 by The Scientist, a leading ... In making the announcement of the first-ever Life ...
Cached Biology Technology:Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors 2 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 2 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 3 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 4 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 5
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... Feb. 5, 2015  Marken is starting its 35 ... has launched a new marketing campaign to solidify its ... The new campaign focuses on First as ... shipments. The first headline in the series, ... priorities with its client,s priorities. Marken recognizes the need ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... corporate website ( http://www.nxt-id.com/ ) as part of its ... wallet. The Company launched its new consumer website for ... Pereira , CEO of NXT-ID said, "Our new corporate ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... 1, 2010 2009 estimates projected that in the United ... diagnosed and 14,600 women would die of the disease. ... onset and a relatively low 5-year survival rate of about ... published in the March 2010 issue of the Journal ...
... The next treatment for cancer might come from fish says ... edition of the FASEB Journal ( http://www.fasebj.org ). ... "docosahexaenoic acid" or "DHA," and its derivatives in the body ... treatments for a wide range of cancers, including neuroblastoma, medulloblastoma, ...
... CITY, March 1, 2010 Like silkworm moths, butterflies and ... instead on dry land. Now, University of Utah researchers have ... how that may make it valuable as an adhesive tape ... western fly fishermen as ,rock rollers, may be useful ...
Cached Biology News:Dietary factors influence ovarian cancer survival rates 2Glue, fly, glue 2Glue, fly, glue 3Glue, fly, glue 4Glue, fly, glue 5